Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators..

N Engl J Med. 2004 Nov 11;351(20):2049-57. Epub 2004 Nov 8. Erratum in: N Engl J Med. 2005 Mar 24;352(12):1276.

2.

The African American Heart Failure Trial: a clinical trial update.

Taylor AL.

Am J Cardiol. 2005 Oct 10;96(7B):44-8. Epub 2005 Aug 9. Review.

PMID:
16226935
5.

Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.

Colvin-Adams M, Taylor AL.

Cleve Clin J Med. 2007 Mar;74(3):227-34. Review.

PMID:
17375804
6.

Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?

Ferdinand KC.

J Law Med Ethics. 2008 Fall;36(3):458-63. doi: 10.1111/j.1748-720X.2008.291.x. Review.

PMID:
18840236
7.

Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.

Echols MR, Yancy CW.

Vasc Health Risk Manag. 2006;2(4):423-31. Review.

8.

African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans.

Ferdinand KC.

Am J Cardiol. 2007 Mar 26;99(6B):3D-6D. Epub 2007 Jan 25. Review.

PMID:
17378993
9.

Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety.

Ferdinand KC.

Expert Rev Cardiovasc Ther. 2005 Nov;3(6):993-1001. Review.

PMID:
16292990
10.

The impact of race on response to RAAS inhibition.

Wallace TW, Drazner MH.

Curr Heart Fail Rep. 2005 Aug;2(2):72-7. Review.

PMID:
16036054
11.

Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.

Franciosa JA.

Expert Opin Pharmacother. 2006 Dec;7(18):2521-31. Review.

PMID:
17150006
12.

Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.

Ferdinand KC, Elkayam U, Mancini D, Ofili E, PiƱa I, Anand I, Feldman AM, McNamara D, Leggett C.

Am J Cardiol. 2014 Jul 1;114(1):151-9. doi: 10.1016/j.amjcard.2014.04.018. Epub 2014 Apr 18. Review.

13.

Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.

Elkayam U, Bitar F.

Am J Cardiol. 2005 Oct 10;96(7B):37i-43i. Epub 2005 Aug 9. Review.

PMID:
16226934
14.
15.

Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.

Cohn JN.

Drugs. 1994;47 Suppl 4:47-57; discussion 57-8. Review.

PMID:
7523062
16.

Racial differences in heart failure therapeutics.

Ishizawar D, Yancy C.

Heart Fail Clin. 2010 Jan;6(1):65-74. doi: 10.1016/j.hfc.2009.08.006. Review.

PMID:
19945062
17.

[Vasodilator therapy in cardiac failure].

Akatsuka N.

Nihon Rinsho. 1993 May;51(5):1276-80. Review. Japanese.

PMID:
8101237
18.

A-HeFT: old dog, new endothelial tricks.

Cohn JN.

Tex Heart Inst J. 2005;32(3):366-8. Review.

19.

Studies of Left Ventricular Dysfunction (SOLVD)--new hope for heart failure.

[No authors listed]

S Afr Med J. 1991 Nov 2;Suppl:1-8. Review. No abstract available.

PMID:
1957226
20.

Heart failure in African Americans: disparities can be overcome.

Sharma A, Colvin-Adams M, Yancy CW.

Cleve Clin J Med. 2014 May;81(5):301-11. doi: 10.3949/ccjm.81a.13045. Review.

Supplemental Content

Support Center